Eqis Capital Management Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,070 shares of the biopharmaceutical company’s stock after purchasing an additional 943 shares during the period. Eqis Capital Management Inc.’s holdings in Gilead Sciences were worth $4,251,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Advisors Preferred LLC acquired a new stake in Gilead Sciences in the second quarter worth $26,000. First Financial Corp IN raised its holdings in Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 401 shares during the period. Legacy Advisors LLC acquired a new stake in Gilead Sciences in the second quarter worth $37,000. Venturi Wealth Management LLC acquired a new stake in Gilead Sciences in the third quarter worth $40,000. Finally, Evolution Wealth Advisors LLC acquired a new stake in Gilead Sciences in the second quarter worth $46,000. Institutional investors own 80.03% of the company’s stock.
In other news, EVP Brett A. Pletcher sold 608 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the completion of the sale, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,750,191.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Brett A. Pletcher sold 2,095 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $66.06, for a total transaction of $138,395.70. Following the sale, the executive vice president now owns 17,826 shares of the company’s stock, valued at approximately $1,177,585.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,288 shares of company stock valued at $1,108,682. Corporate insiders own 0.20% of the company’s stock.
Gilead Sciences stock traded down $0.35 during mid-day trading on Tuesday, reaching $64.29. The company’s stock had a trading volume of 49,208 shares, compared to its average volume of 6,286,513. The company has a market capitalization of $82.72 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 3.47 and a beta of 1.09. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $72.90. The business’s 50 day simple moving average is $64.10 and its 200 day simple moving average is $65.28. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.87 and a current ratio of 2.96.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.01. The business had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.84 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.66 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.92%. The ex-dividend date of this dividend is Thursday, December 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
GILD has been the topic of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. BMO Capital Markets lowered their price objective on shares of Gilead Sciences from $82.00 to $81.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Oppenheimer lowered their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Bank of America initiated coverage on shares of Gilead Sciences in a research report on Wednesday, October 16th. They set a “neutral” rating and a $70.00 price objective for the company. Finally, Credit Suisse Group lowered their price objective on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $78.87.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: What is the QQQ ETF?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.